OptiPEA® GMP Palmitoylethanolamide

Particle Size, Purity and PEA Bioavailability: Choosing a Grade

When formulators evaluate a palmitoylethanolamide (PEA) raw material, two properties dominate the conversation: purity and particle size. The two are often conflated, but they are not the same thing. Purity is a direct measure of ingredient quality; particle size is a formulation characteristic that can be chosen to suit an application. This article sets out what the published literature does – and does not – establish about PEA particle size and oral absorption, and explains why a high-purity Standard grade remains a sound default for most applications. It is a factual, business-to-business overview and makes no health or efficacy claim.

Purity comes first

The single most important quality attribute of a PEA raw material is how much of it is actually PEA. A high-purity grade – OptiPEA® is supplied at ≥99% purity – means a well-defined, consistent, fully characterised starting material with minimal impurities, regardless of its particle size. Much of the published PEA research, and a large share of products on the market, use standard (non-micronised) high-purity PEA. Purity and particle size are independent specifications: a non-micronised grade can be, and OptiPEA® Standard is, every bit as pure as a micronised one. Choosing a particle-size profile is therefore a formulation decision layered on top of a quality foundation that purity already provides.

Why particle size is discussed at all

PEA is a highly lipophilic, poorly water-soluble fatty-acid amide. In their review of its basal pharmacology, researchers note that this property “raises issues concerning its formulation for optimal absorption,” comparing dissolving PEA to “trying to dissolve stones” (Rankin & Fowler, 2020). Because the uptake of a poorly soluble solid can be governed by how quickly it dissolves, physical form is one variable formulators consider. In principle, reducing particle size increases surface area and can raise dissolution rate – the physicochemical rationale behind micronised and ultra-micronised grades (Impellizzeri et al., 2014). Importantly, the same review notes that unprocessed, micronised and ultra-micronised forms are all absorbed after oral intake (Rankin & Fowler, 2020).

What the human evidence actually shows

This is where the literature calls for honesty. A critical pharmacokinetic review concluded that there were “no head-to-head clinical comparisons of unmicronized vs. micronized formulations of PEA”, meaning human clinical evidence that one particle-size form is better absorbed than another is lacking (Gabrielsson et al., 2016). The same authors observed that some preclinical formulations were dissolved before dosing – which bypasses any dissolution-related benefit of micronisation – and that the absolute oral bioavailability of PEA has not been formally established. A later review likewise states that the bioavailability and tissue distribution of PEA are not fully known (Rankin & Fowler, 2020). In other words, the theoretical case for finer particles is reasonable, but a decisive real-world absorption advantage has not been demonstrated.

The preclinical signals – and their limits

Some animal studies have reported particle-size differences. A rodent pharmacokinetic study recorded higher early plasma levels for an ultra-micronised form than for naive (unprocessed) PEA, which the authors read as greater absorbability – while also noting that labelled exogenous PEA can exchange with the body’s endogenous pool, complicating interpretation (Petrosino et al., 2018). A separate rat study found oral differences between grades that disappeared when PEA was given intraperitoneally (Impellizzeri et al., 2014). These are preclinical, model-dependent findings; they point in a direction but do not translate into an established human dosing advantage, and they say nothing about product quality, which purity governs.

Absorption depends on more than particle size

Particle size is only one of several variables. For a lipophilic compound, co-administration with food or fat, the dose, the excipient system, dispersion, and the overall manufacturing process all influence how a finished product behaves. A well-designed Standard-grade formulation can be a perfectly appropriate – and cost-effective – way to deliver high-purity PEA, and remains the most widely used option across the category.

Choosing a grade: a practical view

Rather than ranking grades as “better” or “worse”, it is more accurate to match the grade to the application:

  • Standard (≥99% purity) – the versatile default for capsules, tablets and many powder blends, where a high-purity, well-specified material is what matters most.
  • Micronised – a finer particle-size distribution for formulations where that profile is specifically desired.
  • Ultra-Micronised – an ultra-fine grade for suspension development and specialised applications (available on request).
  • Specify and document – reported particle-size values (D50, Dv10/Dv50/Dv90) depend on the measurement method, so a documented specification supports batch-to-batch consistency whichever grade is chosen.

OptiPEA® is a defined, GMP-manufactured, European-made PEA ingredient supplied at ≥99% purity in Standard, Micronised and Ultra-Micronised grades. The quality of the ingredient is set by its purity, origin and specification; particle size is a formulation choice developers make to suit their format – not a measure of how good the PEA is. Any claims relating to a finished product remain the responsibility of the brand placing it on the market.

Disclaimer. This article is a factual summary of published scientific research on palmitoylethanolamide (PEA) as a molecule, provided for informational and business-to-business purposes. It is not medical advice and does not constitute a health, therapeutic or efficacy claim for OptiPEA® or any finished product. The regulatory status of PEA and of any associated claims varies by country and market; brands are responsible for verifying the permitted status and claims in their own market with qualified regulatory and medical experts. Always consult a healthcare professional regarding any health condition.

Leave a Comment

Your email address will not be published. Required fields are marked *